Recently, various executives in the healthcare industry have taken part in insider selling activity for the stocks of Gilead Sciences, Inc. (NASDAQ:GILD), bluebird bio Inc (NASDAQ:BLUE), and IGI Laboratories, Inc. (NYSE:IG).

Gilead Sciences, Inc.

CEO John C. Martin disposed of 150,000 Gilead Sciences shares, valued at $15,408,914, in four transactions dated September 1. Martin now holds 3,948,066 of the company’s shares that are valued at $398,873,108.

EVP of Corporate and Medical Affairs Gregg Alton unloaded 12,000 shares, valued at $1,232,924, in three transactions dated September 1. Alton now holds 135,422 of the company’s shares that are valued at $13,681,685.

CFO Robin Washington sold 6,250 shares, valued at $638,750, on September 2. The shares were sold via automatic sale program. Washington now holds 94,296 of the company’s shares that are valued at $9,526,725.

Click Here to see the performance of Gilead Sciences insiders.

bluebird bio Inc

Principal Accounting Officer Eric Sullivan unloaded 416 bluebird bio shares, valued at $54,471, in a transaction dated September 2. The shares were sold via automatic sale program. Sullivan now holds 3,218 of the company’s shares that are valued at $406,594.

Director James Mandell sold 1,500 shares, valued at $188,928, in three transactions dated September 1. The shares were sold via automatic sale program.

Click Here to see the performance of bluebird bio insiders.

IGI Laboratories, Inc.

President and CEO Jason Grenfell-Gardner sold 84,048 IGI Laboratories shares, valued at $667,341, in a transaction dated September 1. The shares were sold via automatic sale program. Grenfell-Gardner now holds 187,624 of the company’s shares that are valued at $1,508,497. According to TipRanks.com, which measures corporate insiders’ success based on their transactions, Jason Grenfell-Gardner has an average return of 139.1% and a 100% success rate. Grenfell-Gardner is ranked #5430 out of 33758 corporate insiders.

Click Here to see the performance of IGI Laboratories insiders.